Latham & Watkins Advises Evelo Biosciences in Public Offering of Common Stock

A capital markets team represented the clinical stage biotechnology company in the offering.

June 25, 2020

Evelo Biosciences, Inc., a clinical stage biotechnology company developing orally delivered, systemically acting biologic therapies, has announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, at a public offering price of $3.75 per share, before underwriting discounts and commissions. Evelo also granted the underwriters a 30-day option, solely to cover over-allotments, if any, to purchase up to an additional 1,800,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $45,000,000 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Evelo.

Latham & Watkins LLP represents Evelo Biosciences, Inc. in the offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Adam Johnson and Angel Marcial.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.